Overview

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)

Status:
Terminated
Trial end date:
2018-01-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety and tolerability of ixazomib when administered as multiple oral doses at escalating dose levels in participants with lupus nephritis.
Phase:
Phase 1
Details
Lead Sponsor:
Takeda
Treatments:
Glycine
Ixazomib